Employees want to know that their employers have a vested interest in their health, Vikki Walton, MBA, health equity leader at Mercer, explains.
Employers play an important role in health equity, and Vikki Walton, MBA, health equity leader at Mercer, explained how to improve that through a company’s diversity, equity, and inclusion (DE&I) strategy in a presentation at the Greater Philadelphia Business Coalition on Health (GPBCH).
Transcription
When you begin working with an employer, what are the key starting points to improving health equity?
We go in and we first have the conversation about education. So, we have to educate them. Again, a lot of times employers recognize that with health equity or social determinants of health, they might know a little bit about it, but not so much. So, we go in and we have to educate staff around exactly what it means. And then we go in and we start to assess their actual benefits. We go in and do a deep dive into what they're offering and then tie it to different groups of cohorts.
So, if we are looking at the LGBTQ+ community, what are they doing around gender-affirming care? If we're looking at women, reproductive health, what are we doing? What are we offering? How can we support that? What does travel and lodging look like for those who want to have care at centers of excellence? So we go in and we do a deep dive, which will take some time, to assess what they currently offer.
We also do data harvesting. What does your data look like? As we start to support your inclusive benefits, what are we seeing with populations? So we go in and look at that. We also look at social determinants of health, where we look at the social vulnerability index to identify are there populations that are experiencing access to care. How can we support that? So, we take a methodical approach to assessing their overarching benefit platform, and then from there, start to look at what those interventions might look like.
Are there any research areas of interest?
Yeah, so the question always comes up of, well, what's the return on investment? How can we identify whether we’re being effective if this is our approach? We have seen research with the AMA [American Medical Association] that has looked at employers’ role and how a healthy employee will support a healthy workforce, and the importance of that. We've had surveys from employees saying,“This is what we want and we’re interested in having employers take a vested interest in our health and specifically targeted groups.”
But we also look at utilization and employee engagement, and then overarching outcomes as we develop. So as far as research, it's kind of individualized depending on what the employer is looking to gain. And then over time, I believe we'll be able to harvest and have robust outcomes data to support when employers start to improve the access and be more strategic and intentional when it comes to certain cohorts.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discuss innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More